Enclomiphene Dosage: 12.5 mg vs 25 mg and What Trials Used

Every enclomiphene dosage used in practice today traces back to a small set of clinical trials run by Repros Therapeutics. Those trials tested three daily doses: 6.25 mg, 12.5 mg and 25 mg. The two that went forward into the larger studies were 12.5 mg and 25 mg taken once a day by mouth.

The first dose-finding study was published by Wiehle and colleagues in BJU International in 2013. It enrolled 48 men with low testosterone and compared the three enclomiphene doses with a 5 g daily testosterone gel for 6 weeks. The 25 mg dose produced the highest testosterone of the three, an average of 604 ng/dL at day 42, against 500 ng/dL on the gel.

The later phase IIB trial (Wiehle, Fertility and Sterility, 2014) and the two phase III trials (Kim, BJU International, 2016) used 12.5 mg and 25 mg daily. The phase III design allowed titration between the two doses based on testosterone levels, although the exact titration rules are not described in the published abstract.

This means the evidence base for enclomiphene dosage is limited to 12.5 to 25 mg once daily, in men with secondary hypogonadism, for up to about 4 months. Any dose outside that range, or any schedule other than daily, has no trial behind it. For what the drug is and how it works, see the enclomiphene guide.

The phase IIB trial is the clearest head-to-head comparison of the two options for enclomiphene dosage. It randomized 124 men to enclomiphene 12.5 mg, 25 mg, testosterone gel or placebo for about 3 months.

The surprise is that the higher dose did not give higher testosterone. Men on 12.5 mg ended the study with an average of 472 ng/dL, while men on 25 mg averaged 406 ng/dL, even though LH and FSH rose more on 25 mg. The spread within each group was wide, with standard deviations over 160 ng/dL, so this does not prove that 12.5 mg is better, only that doubling the dose does not double the result.

Side effects point the same way. Four men stopped the phase IIB trial because of mild to moderate adverse events, and all four were in the 25 mg group; the events described include hives, loss of sensation at climax, and nausea. For men starting out, this is why 12.5 mg is the usual first enclomiphene dosage, with 25 mg kept for those whose testosterone stays low on follow-up labs.

The timeline is one of the better documented parts of the drug. In both phase II studies, testosterone rose significantly within 2 weeks of starting. In the phase III trials, testosterone reached a steady level above 400 ng/dL "after 4 weeks of treatment", according to Kim and colleagues.

That gives a practical rule: blood work at about 4 weeks shows where a given enclomiphene dosage has settled. Testing earlier catches a level that is still rising; testing much later wastes time if the dose is wrong. Forum users on ExcelMale and MESO-Rx most often report taking their first follow-up labs at around 4 weeks, which lines up with the trial data.

The effect also fades on a known schedule. In the Wiehle 2013 study, the effect on LH and testosterone persisted for at least 1 week after stopping. In the Kaminetsky 2013 study (Journal of Sexual Medicine), testosterone returned to its starting value 1 month after the last dose. Enclomiphene does not permanently change hormone production; it works only while it is taken.

Morning blood draws matter because testosterone is highest early in the day. The phase IIB trial drew blood at 9:00 am in a fasting state, so comparing a morning baseline with an afternoon follow-up can make the drug look weaker than it is.

Enclomiphene has a half-life of about 10.5 hours, according to Wiehle and colleagues (2014). That short half-life is why the trials used once-daily dosing: the drug level falls substantially within a day. It is very different from the zuclomiphene in Clomid, which has a half-life of about 30 days and builds up with daily use.

There is no trial data on the best time of day to take enclomiphene. Because the drug level does not line up neatly with the rise in LH (Wiehle 2013 found no temporal link between peak drug levels and peak LH or testosterone), the time of day is less important than taking it consistently at the same time.

Every other day dosing is common on forums and in some telehealth plans, but it was not tested in the trials. User reports on ExcelMale vary widely. One man reported that 12.5 mg every other day let his testosterone fall to 360 ng/dL and his symptoms return; another held 912 ng/dL on the same schedule; a third settled in the low to mid 500s. These are individual accounts and have not been confirmed in studies. The lasting effect on LH for about a week after stopping may explain why some men hold their levels on alternate days, but only a follow-up blood test shows which group a given man falls into.

Searches for enclomiphene dosage for bodybuilding and for post-cycle therapy are common, but no clinical trial has studied either use. The trials enrolled men with naturally low testosterone and working testes, not men recovering from anabolic steroids.

What can be said from the trial data is limited. Enclomiphene raises LH and FSH, and in the phase IIB trial LH roughly doubled on both doses within 3 months. In men whose natural production is suppressed after a steroid cycle, that is the signal needed for recovery. Clomiphene has been used in men since the 1970s and is widely used after cycles, which is covered in our Clomid PCT guide. But the doses and durations used in bodybuilding circles come from experience, not from studies, and recovery after long or heavy cycles is not guaranteed by any of these drugs.

For athletes in tested sport, clomifene is banned at all times under the anti-estrogenic substances section of the 2026 WADA Prohibited List. Enclomiphene is not named separately, but it falls within the same class of selective estrogen receptor modulators.

Changes to enclomiphene dosage should follow lab results, not how a man feels in the first week. A sensible approach, based on what the trials measured, looks like this:

Common side effects and warning signs are covered in enclomiphene side effects. Men comparing options should also read enclomiphene vs Clomid, since the two differ mainly in how long they stay in the body.

Clomid.org is an independent educational resource. We are not affiliated with any pharmaceutical manufacturer, compounding pharmacy, telehealth company or healthcare provider. This content is for informational purposes only and does not constitute medical advice. Images on this site are illustrative artwork made for editorial purposes; they do not show real products, packaging or labels and are not an advertisement or an offer to sell.